  Pancreatic cancer has poor prognosis because of its rapid progression and treatment resistance. Based on the results of the Metastatic Pancreatic Adenocarcinoma Clinical Trial ( MPACT) , a combination regimen of gemcitabine with nab-paclitaxel is currently used as standard therapy for the treatment of metastatic pancreatic cancer. However , because studies in Asian populations are lacking , we investigated the treatment efficacy and safety of this combination therapy in Korean population. Patients with metastatic pancreatic cancer ( n = 81) treated with gemcitabine and nab-paclitaxel ( 1,000 and 125 mg/m